Influence of Home Monitoring on the Clinical Status of Heart Failure Patients

Hindricks et al., The Lancet 2014

Study Design

  • Randomized, controlled, international, multicenter study
  • Assesses the impact of BIOTRONIK Home Monitoring® on the clinical status of heart failure patients
  • 664 patients at 36 centers

Key Result 1

At 12 months follow-up, significantly fewer patients in the BIOTRONIK Home Monitoring® group worsened according to the modified Packer score compared to the control group (18.9% vs27.5%; p<0.05).

Primary Endpoint of INTIME

Key Result 2

Significant reduction of all-cause mortality in heart failure patients of more than 60% and beneficial effect on the composite clinical score with implant-based (ICD or CRT-D) BIOTRONIK Home Monitoring® compared to standard care.

Secondary Endpoint of INTIME

Clinical Relevance

  • The IN-TIME study demonstrated improved clinical status for heart failure patients by implementing a remote monitoring system based on:
  • A reliable transmission rate of 85%
  • A clinically relevant set of rhythmological and technical parameters
  • Clinical workflow that enables fast patient contact and follow-up within one to two working days
  • The European Society of Cardiology added a clear recommendation for the use of implant-based remote follow-up to its guidelines1

Study Objective
  • Assessment of the impact of BIOTRONIK Home Monitoring® on the clinical status of heart failure patients
1° Endpoints
  • Modified Packer score: based on death, hospitalization, change in NYHA class, patient’s global self-assessment score
2° Endpoints
  • All–cause mortality
  • Number of HF hospitalizations and length(s) of stay
Clinical Sites
  • 36 centers (Australia, Austria, Czech Republic, Denmark, Germany, Israel and Latvia)
Sample Size
  • 664 patients
Inclusion Criteria
  • ICD indication (dual-chamber ICD, CRT-D)
  • Chronic heart failure
  • NYHA class II or III
  • LVEF ≤ 35%
Main Exclusion Criteria
  • Permanent atrial fibrillation
  • ICD and CRT-D
    Study Flowchart
    • 12 months after randomization
    Study Duration
    • July 2007 - December 2010
    Reference no.
    • NCT00538356
    Principal Investigators
    • Prof. Dr. Gerhard Hindricks, Herzzentrum Leipzig, Germany

    Download Section

    Related Products

    Cardiac Resynchronization Therapy

    BIOTRONIK offers an extensive product portfolio in the area of Cardiac Resynchronization.

    Tachycardia Therapy

    Cardiac Remote Monitoring

    BIOTRONIK offers Home Monitoring for its complete product portfolio.

    Monitoring Teaser

    1 Brignole M et al. 2013 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy. European Heart Journal. 2013, 34(29).